Intravitreal bevacizumab for choroidal neovascularization in toxoplasmosis.
Guthoff
Rainer
R
Goebel
Winfried
W
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology*; D002833:Choroiditis / Q000150:complications / Q000469:parasitology*; D005260:Female; D006801:Humans; D007267:Injections; D010778:Photochemotherapy; D012008:Recurrence; D012173:Retinitis / Q000150:complications / Q000469:parasitology*; D014123:Toxoplasmosis; D014222:Triamcinolone Acetonide / Q000008:administration & dosage; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide